{
    "nctId": "NCT05103644",
    "briefTitle": "Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients\"",
    "officialTitle": "Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients\"",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Ki-67 molecular",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Confirmed breast cancer any stage confirmed by radiological and pathological or by clinical evaluation undergo surgery or receiving neo/adjuvant chemotherapy treatment\n2. Age above 18 years\n3. HER2 negative core biopsy\n4. Adequate renal function: the calculated creatinine clearance should be \u226550 mL/min\n5. Patients must be accessible for treatment and follow-up\n6. Performance status of Eastern Cooperative Oncology Group (ECOG) \u2264 2\n\nExclusion Criteria:\n\n1. Known hypersensitivity reaction to the investigational compounds or incorporated substances\n2. patients who are unlikely to comply with trial requirements (eg, confusion, psychological or mood disturbances ,alcoholism, cardiac arrhythmia)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}